Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment

Mild Cognitive Impairment Clinical Trial

Official title:

A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02211560
• Other study ID #: Vayacog_002
• Status: Terminated
• Phase: N/A
• First received: August 6, 2014
• Last updated: February 1, 2018
• Start date: September 2014
• Est. completion date: December 25, 2017

Study information

• Verified date: February 2018
• Source: Enzymotec
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective is to evaluate the efficacy and safety of phosphatidylserine (PS) on cognitive abilities in MCI

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 97
• Est. completion date: December 25, 2017
• Est. primary completion date: December 25, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Age greater than or equal to 65 and less than or equal to 85 years.

2. Formal education greater than or equal to 10 years.

3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) 3. Male or female with a diagnosis of Mild Cognitive Impairment (MCI) as defined by Peterson, according to The following:

3.1 Clinical Dementia Rating Scale total score (CDR) =0.5, and score of each one of the six categories ("box scores") = 1. 3.2 Mini Mental State Exam > 24 3.3 Verbal Paired-Associated Learning test score according to the following ages: Ages 65-70 less than or equal to 18 Ages 71-85* less than or equal to 17

*Eligibility of subjects aged between 70 and 71 (i.e., 70.1) will be evaluated according to 71-85 age group score.

4. Adequate vision, hearing, and literacy ability to allow for neuropsychological testing.

5. Able and willing to perform all study procedures.

6. Ability to provide written consent signed by the subject

Exclusion Criteria:

1. Any significant neurological condition or disorder (e.g., seizure disorder, epilepsy, brain tumors, stroke, etc.) that could cause cognitive deterioration other than suspected MCI.

2. Any medical condition or disorder that could produce cognitive deterioration (i.e., renal, respiratory, cardiac, and hepatic disease, diabetes mellitus, endocrine, metabolic or hematological disturbances) unless well controlled for at least 3 months.

3. Clinically significant abnormal serum TSH and/or B-12 and/or folic acid levels below the normal range.

4. History of any infective or inflammatory brain disease including viral, fungal or syphilitic etiologies.

5. Head trauma or injury immediately preceding cognitive deterioration, unless over 2 years have passed since full cognitive and functional recovery.

6. Depression at screening as assessed by Geriatric Depression Scale-short version (score =5)

7. Current suicidality at screening by Columbia Suicidality Severity Rating Scale.

8. Dementia by DSM-IV criteria.

9. Concomitant use of medications with potent psychotropic properties (e.g. antipsychotics, ADHD treatments, lithium carbonate, anti-epileptic drugs such as Gabapentin). Sedating antihistamines are allowed if administered last dose is administered at least 12 hours before cognitive testing. Usage of prescription or nonprescription antidepressant agents, lipid lowering medications, and anti-hypertensive medications with a stable dosage for more than 2 months prior study entry is permitted.

10. Concomitant use of any medications approved for the symptomatic treatment of dementia due to AD (e.g., NMDA, acetyl choline esterase inhibitors)

11. Use within 3 weeks prior to study entry of any medications with any anti-cholinergic effect (e.g. Atropine, Scopolamine, Tolterodine, Hyoscyamine, Biperiden, Benzatropine, Trihexyphenidyl, Oxybutynin).

12. Use within 4 weeks prior to the study entry of dietary supplements containing DHA, EPA, Phosphatidylserine, Phosphatidylcholine (e.g. Krill oil, Lecithin), or alpha-glycerphosphocholine (GPC).

13. Use within 4 weeks prior to the study entry of medical foods indicated for cognitive or memory impairment [e.g. Axona, Cerefolin, CerefolinNAC, Souvenaid].

14. Concomitant use of any supplements containing ingredients with nootropic or vasodilator properties (e.g., Ginkgo Biloba, Vinpocetine, Piracetam, high energy supplements).

15. Use of an investigational drug within the last 30 days.

16. Allergic reaction or sensitivity to marine products (fish/seafood) and/or soy.

17. Any known condition which in the opinion of the investigator may be possibly causing cognitive impairment other than AD (mania, alcohol or substance abuse, mental retardation, bipolar disorder, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, psychotic disorder, major psychiatric disorder preceding dementia onset or affecting brain function, major surgery ) and/or limits the successful trial completion

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Other:
• Phosphatidylserine

• Placebo

Locations

Country	Name	City	State
Israel	Rambam medical center, Israel	Haifa
Israel	Ichilov medical center	Tel-Aviv
United States	Lehigh Center for Clinical Research	Allentown	Pennsylvania
United States	Integrative Clinical Trials, LLC	Brooklyn	New York
United States	Great Lakes Clinical Trials	Chicago	Illinois
United States	Memory Enhancement Center of America	Eatontown	New Jersey
United States	Pharmacology Research Institute	Encino	California
United States	New West Physicians, PC	Golden	Colorado
United States	Pharmacology Research Institute	Los Alamitos	California
United States	Miami Jewish Health Systems	Miami	Florida
United States	The Medical Research Network	New York	New York
United States	Pharmacology Research Institute	Newport Beach	California
United States	APG Research LLC	Orlando	Florida
United States	Princeton Medical Institute	Princeton	New Jersey
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Enzymotec

Countries where clinical trial is conducted

United States,  Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Safety of phosphatidylserine versus placebo treatment	Clinical laboratory safety data will be collected at baseline and 24 months. Vital signs will be measured at baseline, 12 and 24 months. Adverse events (including changes to concomitant medications) will be documented at all study visits (i.e baseline, 3, 6, 12, 18 and 24 months).	baseline, 3, 6, 12, 18 and 24 months
Primary	Difference in change in the Selective Reminding Test (SRT) between the study groups.		baseline, 3, 6,12 months
Secondary	Mini Mental State Examination (MMSE)		baseline, 12 and 24 months
Secondary	Computerized Neurological battery test (NBT)		baseline, 6, 12 and 24 months
Secondary	Transition rate to dementia according to DSM-4 criteria		baseline, 3, 6, 12, 18 and 24 months
Secondary	Mini Sleep Questionnaire (MSQ)		baseline, 12 and 24 months
Secondary	Hamilton Anxiety Rating Scale (HAM-A).		baseline, 12 and 24 months
Secondary	Selective Reminding Test (SRT)		18 and 24 months